PE20070353A1 - Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol - Google Patents
Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamolInfo
- Publication number
- PE20070353A1 PE20070353A1 PE2006000973A PE2006000973A PE20070353A1 PE 20070353 A1 PE20070353 A1 PE 20070353A1 PE 2006000973 A PE2006000973 A PE 2006000973A PE 2006000973 A PE2006000973 A PE 2006000973A PE 20070353 A1 PE20070353 A1 PE 20070353A1
- Authority
- PE
- Peru
- Prior art keywords
- acid
- hfc
- salbutamol
- citrate
- hydrochloride
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title abstract 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 title abstract 2
- OWNWYCOLFIFTLK-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;hydron;chloride Chemical compound Cl.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 OWNWYCOLFIFTLK-UHFFFAOYSA-N 0.000 title 1
- 229960002052 salbutamol Drugs 0.000 title 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- WXGNWUVNYMJENI-UHFFFAOYSA-N 1,1,2,2-tetrafluoroethane Chemical compound FC(F)C(F)F WXGNWUVNYMJENI-UHFFFAOYSA-N 0.000 abstract 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 abstract 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 abstract 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 abstract 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 abstract 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 235000015165 citric acid Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 239000001630 malic acid Substances 0.000 abstract 1
- 235000011090 malic acid Nutrition 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 229910017604 nitric acid Inorganic materials 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
- C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
- C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA FORMULACION DE UNA DISOLUCION PARA AEROSOL QUE COMPRENDE: A) SAL DE SALBUTAMOL DE ADICION DE ACIDO (HIDROCLORURO O CITRATO) COMPRENDIDA ENTRE 0,001-1%; B) UN PROPELENTE DE HFC SELECCIONADO ENTRE HFC-134(a), HFC-227, HFC-134 Y MEZCLAS DE LOS MISMOS; C) UN DISOLVENTE CONJUNTO; D) UN ACIDO INORGANICO TALES COMO HCl, ACIDO SULFURICO, ACIDO NITRICO, ACIDO FOSFORICO, O UNO ORGANICO TALES COMO ACIDO ASCORBICO, ACIDO CITRICO, ACIDO LACTICO, ACIDO MALICO, ENTRE OTROS. ADICIONALMENTE PUEDE CONTENER UNA SUSTANCIA FARMACOLOGICA TAL COMO BROMURO DE IPRATROPIO. DICHA FORMULACION ES ADECUADA PARA SU ADMINISTRACION MEDIANTE INHALADORES DE DOSIS MEDIA EN EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05017599 | 2005-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070353A1 true PE20070353A1 (es) | 2007-04-19 |
Family
ID=35564491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000973A PE20070353A1 (es) | 2005-08-12 | 2006-08-10 | Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070041911A1 (es) |
| AR (1) | AR057745A1 (es) |
| PE (1) | PE20070353A1 (es) |
| TW (1) | TW200800141A (es) |
| UY (1) | UY29740A1 (es) |
| WO (1) | WO2007020204A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0501956D0 (en) * | 2005-01-31 | 2005-03-09 | Arrow Internat | Nebulizer formulation |
| GB201108039D0 (en) | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
| GB201117619D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
| GB201117621D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
| GB201306984D0 (en) | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
| CA3007050C (en) | 2015-12-04 | 2020-12-08 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition comprising a formoterol compound |
| CN109715160A (zh) | 2016-09-19 | 2019-05-03 | 墨西哥氟石股份公司 | 药物组合物 |
| ES2877575T3 (es) | 2016-09-19 | 2021-11-17 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende salmeterol |
| CN114515284A (zh) | 2016-09-19 | 2022-05-20 | 墨西哥氟石股份公司 | 药物组合物 |
| EP3801457A1 (en) * | 2018-06-04 | 2021-04-14 | Lupin Inc. | Stable pharmaceutical compositions for pressurized metered dose inhalers |
| FR3130554A1 (fr) * | 2021-12-20 | 2023-06-23 | Aptar France Sas | Composition pharmaceutique comprenant du salbutamol |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8828477D0 (en) * | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| WO1992022287A1 (en) * | 1991-06-10 | 1992-12-23 | Schering Corporation | Non-chlorofluorocarbon aerosol formulations |
| JP2003221335A (ja) * | 2001-10-26 | 2003-08-05 | Dey Lp | 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法 |
| CN1216600C (zh) * | 2002-04-24 | 2005-08-31 | 信谊药厂 | 盐酸左旋沙丁胺醇气雾剂及制备工艺 |
| CN1228045C (zh) * | 2003-11-03 | 2005-11-23 | 王立强 | 口腔速崩速溶片制剂及其制备方法 |
| GB0406069D0 (en) * | 2004-03-17 | 2004-04-21 | Thompson James | Process |
-
2006
- 2006-08-04 WO PCT/EP2006/065090 patent/WO2007020204A2/en active Application Filing
- 2006-08-09 US US11/463,477 patent/US20070041911A1/en not_active Abandoned
- 2006-08-10 PE PE2006000973A patent/PE20070353A1/es not_active Application Discontinuation
- 2006-08-11 UY UY29740A patent/UY29740A1/es not_active Application Discontinuation
- 2006-08-11 TW TW095129480A patent/TW200800141A/zh unknown
- 2006-08-11 AR ARP060103518A patent/AR057745A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UY29740A1 (es) | 2007-03-30 |
| TW200800141A (en) | 2008-01-01 |
| AR057745A1 (es) | 2007-12-12 |
| US20070041911A1 (en) | 2007-02-22 |
| WO2007020204A2 (en) | 2007-02-22 |
| WO2007020204A3 (en) | 2007-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070353A1 (es) | Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol | |
| AR101593A2 (es) | Formulación superfina de formoterol | |
| AR038641A1 (es) | Formulacion superfina de formoterol | |
| AR079726A1 (es) | Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes | |
| PE20080204A1 (es) | Formulaciones farmaceuticas que comprenden un anticolinergico y un beta agonista | |
| AR059350A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
| DE60114571D1 (de) | Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung | |
| RS52940B (en) | PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS | |
| AR123674A2 (es) | Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona | |
| AR040450A1 (es) | Formulacion superfina de salmeterol | |
| CL2023000998A1 (es) | Formulación farmacéutica para inhalador presurizado de dosis medidas | |
| RS54874B1 (sr) | Upotreba kompozicije koja obuhvata formoterol i beklometazon dipropionat za tretman egzacerbacije astme | |
| ES2542177T3 (es) | Uso de osmolitos obtenidos de bacterias extremófilas para la fabricación de medicamentos inhalables para la prevención y el tratamiento de enfermedades pulmonares y cardiovasculares, así como un dispositivo de inhalación que contiene osmolitos como componentes activos | |
| PE20011271A1 (es) | Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares | |
| AR085273A1 (es) | Formulacion liquida libre de propelente que comprende una droga antimuscarinica | |
| NO20074854L (no) | Farmasoytiske aerosolformuleringer for komprimerte, utmalte doseinhalatorer omfattende et sekvestreringsmiddel | |
| UY30935A1 (es) | Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones. | |
| CO6270213A2 (es) | Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion | |
| RS53883B1 (en) | IMPROVED MEDICAL FORMULATIONS IN THE FORM OF AEROSOL | |
| AR038764A1 (es) | Formulacion de una solucion de inhalacion con una sal de tiotropio | |
| AR094287A1 (es) | Metodos y composiciones para administracion de oxibutinina | |
| BR112012027000A2 (pt) | fármaco para tuberculose a base de perclorato de 4-tioureído-iminometilpiridínio: método de preparação e tratamento | |
| TH86643A (th) | สูตรผสมสารละลาย hfc ที่มีแซลบูทามอล ไฮโดรคลอไรด์ หรือ แซลบูทามอล ซิเทรท | |
| AR026682A1 (es) | Compuesto de carbapenem, uso del mismo y de su compuesto intermediario | |
| BR0303347A (pt) | Formulações de aerossol contendo ésteres de derivados de 3,17-diidroxi estratieno para deposição pulmonar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |